骨形态发生蛋白4浓度与肥胖中脂肪分布的新关联及艾塞那肽对其的干预作用。
New association of bone morphogenetic protein 4 concentrations with fat distribution in obesity and Exenatide intervention on it.
作者信息
Wang Xingchun, Chen Jiaqi, Li Liang, Zhu Cui Ling, Gao Jingyang, Rampersad Sharvan, Bu Le, Qu Shen
机构信息
Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital of Tongji University, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai, 200072, China.
Department of Endocrinology and Metabolism, Suzhou Municipal Hospital, Suzhou, Jiangsu Province, 215000, China.
出版信息
Lipids Health Dis. 2017 Apr 4;16(1):70. doi: 10.1186/s12944-017-0462-1.
BACKGROUND
Bone morphogenetic protein 4 (BMP-4) has been proven to regulate white adipogensis. We aimed to demonstrate the correlation of BMP-4 with fat distribution and Exenatide treatment on it.
METHODS
We enrolled 69 obese patients. Anthropometric and metabolic indexes were collected. Fat distribution was measured by dual-energy X-ray absorptiometry. BPM-4 levels were assessed using enzyme-link immunosorbent assay kit. 30 obese patients were treated with Exenatide twice a day. Change in body weight, metabolic-related indices and BPM-4 levels were evaluated after 18 weeks.
RESULTS
- The mean(±SD) BMP-4 levels were 763.98 ± 324.11 pg/ml in the obese. BPM-4 levels were significantly positively correlated with estimated visceral adipose tissue mass in all subjects and also in females (r = 0.377, r = 0.625, respectively,all P < 0.05). BPM-4 levels were also significantly positively correlated with body mass index, hip circumference and total fat% in females (r = 0.375,r = 0.429,r = 0.493,respectively, all P < 0.05). BPM-4 levels were negatively correlated with total cholesterol(TC) in all subjects and males also (r = -0.373,r = -0.332,respectively, all P < 0.05). BPM-4 levels were also significantly positively correlated with free triiodothyronine in males (r = 0.441, P < 0.05). 3) Multivariate analyses showed that TC was risk factor of BMP-4 concentration in males and Est.VAT Area was risk factor of BMP-4 levels in females. 4) BMP-4 levels were significantly higher in the obesity with slightly increased thyroid stimulating hormone(TSH) than the obesity without slightly increased TSH (902.08 ± 354.74 pg/ml vs. 720.24 ± 306.41 pg/ml, P < 0.05). 5) Exenatide treatment leads to a significant decreased in BMP-4 from 860.05 ± 352.65 pg/ml to 649.44 + 277.49 pg/ml independent of weight loss(P < 0.05).
CONCLUSION
BMP-4 levels were associated with the visceral adipose tissue and may play a certain role in fat distribution and subclinical hypothyroidism in obesity. Exenatide treatment reduced BMP-4 levels independent of weight loss.
TRIAL REGISTRATION
Clinicaltrials.gov Identifier: NCT02118376 , Registered 16 April.
背景
骨形态发生蛋白4（BMP - 4）已被证明可调节白色脂肪生成。我们旨在证明BMP - 4与脂肪分布的相关性以及艾塞那肽对其的治疗作用。
方法
我们纳入了69名肥胖患者。收集人体测量和代谢指标。采用双能X线吸收法测量脂肪分布。使用酶联免疫吸附测定试剂盒评估BPM - 4水平。30名肥胖患者每天接受两次艾塞那肽治疗。18周后评估体重、代谢相关指标和BPM - 4水平的变化。
结果
1）肥胖患者中BMP - 4水平的均值（±标准差）为763.98±324.11 pg/ml。在所有受试者以及女性中，BPM - 4水平与估计的内脏脂肪组织质量显著正相关（分别为r = 0.377，r = 0.625，均P < 0.05）。在女性中，BPM - 4水平也与体重指数、臀围和总脂肪百分比显著正相关（分别为r = 0.375，r = 0.429，r = 0.493，均P < 0.05）。在所有受试者以及男性中，BPM - 4水平与总胆固醇（TC）呈负相关（分别为r = -0.373，r = -0.332，均P < 0.05）。在男性中，BPM - 4水平也与游离三碘甲状腺原氨酸显著正相关（r = 0.441，P < 0.05）。3）多变量分析表明，TC是男性BMP - 4浓度的危险因素，估计的内脏脂肪组织面积是女性BMP - 4水平的危险因素。4）甲状腺刺激激素（TSH）略有升高的肥胖患者中的BMP - 4水平显著高于TSH没有略有升高的肥胖患者（902.08±354.74 pg/ml对720.24±306.41 pg/ml，P < 0.05）。5）艾塞那肽治疗导致BMP - 4从860.05±352.65 pg/ml显著降至649.44 + 277.49 pg/ml，与体重减轻无关（P < 0.05）。
结论
BMP - 4水平与内脏脂肪组织相关，可能在肥胖的脂肪分布和亚临床甲状腺功能减退中起一定作用。艾塞那肽治疗可降低BMP - 4水平，与体重减轻无关。
试验注册
Clinicaltrials.gov标识符：NCT02118376，4月16日注册。
Zotero 插件